Last updated: July 27, 2025
Introduction
China patent CN103298819, filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., encompasses an innovative approach within the pharmaceutical landscape aimed at addressing key therapeutic challenges. This patent appears to focus on the development of novel compounds, formulations, or methods that enhance treatment efficacy, stability, or bioavailability, aligning with China's strategic emphasis on pharmaceutical innovation. An exhaustive analysis of this patent's scope, claims, and the surrounding patent landscape reveals critical insights for stakeholders in the intellectual property (IP) and pharmaceutical sectors.
Patent Overview
CN103298819 is classified within the Capital Equipment or Chemical or Pharmaceutical Subclasses under the International Patent Classification (IPC) codes—notably those related to organic compounds, pharmaceuticals, or medical compositions. The patent was granted in 2014, suggesting that its filing likely dates back to at least 2012, placing it within a mature stage of patent lifecycle.
The patent describes a novel compound or composition, likely with therapeutic application, potentially emphasizing its method of preparation, pharmaceutical composition, or specific use cases. Such claims typically aim to protect the inventive aspects of the compound's structure, formulation, or use method.
Scope of the Patent
Key Technical Focus
While specific claim language is necessary for precise scope interpretation, based on standard practices and available patent documents, CN103298819 broadly covers:
- Novel chemical entities with specific structural formulas,
- Pharmaceutical compositions comprising the compound,
- Methods of synthesis or preparation of the compound,
- Therapeutic methods involving the compound for certain indications.
The inclusion of claims related to specific structural features suggests an emphasis on chemical novelty, while those covering methodologies or use cases extend the scope into treatment methods.
Claims Analysis
Patent claims in this case are likely structured as:
- Independent Claims: Covering the core compound or composition, defining the structure by specific chemical formulae or classes, and method of production.
- Dependent Claims: Detailing specific embodiments, such as particular substituents, dosage forms, or application methods.
Sample claim structure (hypothetical):
- “A compound with the following chemical structure: [detailed structural formula], wherein R1, R2, R3 are...,”
- “A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier,”
- “A method for treating [disease] in a subject, comprising administering an effective amount of the compound of claim 1.”
The breadth of these claims indicates an attempt to secure a comprehensive patent barrier around the core invention, covering its chemical structure, preparation, and application.
ClaimScope and Limits
The scope includes vertebrate health indications, likely encompassing conditions such as cancer, inflammatory diseases, or metabolic disorders, considering the common focus of such compounds in Chinese pharmaceutical patents. The claims' relative breadth aims to prevent competitors from developing similar compounds or methods.
Patent Landscape and Competitive Position
Preceding Art and Patent Space
CN103298819 exists within a competitive field, characterized by numerous patents filed by domestic and international entities targeting similar therapeutic targets or chemical classes. Major players include international pharmaceutical companies and Chinese firms engaging actively in innovative drug development.
Upstream, prior art includes earlier patents and publications covering related chemical structures and methods. For example, patents focusing on 5-HT receptor modulators, kinase inhibitors, or antineoplastic agents could be relevant prior art, requiring CN103298819 to demonstrate novelty and inventive step.
Patents Citing CN103298819
Citations from later patents indicate that CN103298819 has served as prior art reference in patent filings exploring analogous compounds or improved formulations. These subsequent filings often seek to:
- Broaden the scope via substituted compounds,
- Cover alternative synthesis pathways,
- Seek specific therapeutic claims.
This dynamic suggests that CN103298819 plays a significant role in shaping a niche within the Chinese pharmaceutical patent space, serving as either a foundational patent or a blocking patent.
Legal Status and Lifespan
Given its issuance date, CN103298819 likely enjoys 20-year protection from its earliest priority date (probably around 2010–2012). Its legal status should be regularly monitored, particularly for maintenance fee payments, to maintain enforceability.
Implications for Stakeholders
- Innovators can leverage the patent’s claims to prevent similar compounds’ commercialization within China.
- Generic manufacturers need to analyze the scope to identify potential design-around options or contestability avenues.
- Investors should recognize the patent's breadth as a marker of the innovator's strategic IP position within the Chinese pharmaceutical market.
Challenges and Opportunities
- The patent's narrow or broad claims impact how easily competitors can circumvent it.
- The ongoing development of biosimilar or alternative therapeutic agents raises questions about patent robustness.
- Given China's rapidly evolving IP landscape, opportunities exist for filing divisional or improvement patents to extend patent life or broaden protection.
Conclusion
CN103298819 exemplifies the strategic use of comprehensive chemical and method claims to secure a pioneering position in China's pharmaceutical patent landscape. Its scope covers critical aspects of novel compounds, their preparation, and therapeutic application, thus serving as both an asset and a potential barrier to competitors. Understanding its claims and landscape positioning is vital for businesses involved in drug development, licensing, or litigation in China.
Key Takeaways
- Broad Claim Coverage: CN103298819 solidifies patent rights over specific chemical structures, formulations, and uses, demanding a detailed understanding for potential design-arounds.
- Strategic Position: It acts as a cornerstone patent within its therapeutic niche, influencing subsequent filings.
- Landscape Insights: It faces competition from other patents targeting similar compounds, necessitating vigilant landscape monitoring.
- Legal and Commercial Significance: Protects the innovator’s market edge within China’s fast-growing pharmaceutical sector.
- Continual Evolution: The patent landscape is dynamic; further filings and legal challenges could affect the patent’s enforceability and scope.
FAQs
Q1: What is the main therapeutic application likely covered by CN103298819?
While specific claims are needed for certainty, similar patents generally focus on treating conditions such as cancer, inflammatory diseases, or metabolic disorders.
Q2: Can competitors develop similar compounds around CN103298819?
Yes, by designing structurally different compounds that do not infringe on the specific claims; however, careful analysis of claim language is essential.
Q3: How does the patent landscape in China influence the development of similar drugs?
It creates a legal framework that offers protection but also encourages strategic patent filing, licensing, or litigation as competitive tools.
Q4: What are crucial considerations for maintaining CN103298819’s patent rights?
Timely payment of maintenance fees, vigilant monitoring of infringement, and potential filing of divisional or improvement patents.
Q5: How does this patent impact global drug development efforts?
Generally, China patents are geographically limited; however, their scope can influence international patent strategies and patent challenging activities.
Sources
- Chinese Patent Office database – Patent CN103298819 data and legal status.
- CIPO and SIPO patent classification manuals – Relevant technical classifications.
- Industry reports – Trends in Chinese pharmaceutical patent filings.
- Legal analysis articles – Enforcing and challenging Chinese pharma patents.
- Chia Tai Tianqing’s patent portfolio documentation – Additional context on strategic patenting.
